Co-Delivery of Doxorubicin and Schisandrin B by Liposome to Overcome Multidrug Resistance
- Author:
Tian-Ao LI
1
Author Information
- Publication Type:Journal Article
- Keywords: Doxorubicin; Liposome; Multidrug resistance; Schisandrin B; Synergistic effect
- From: Chinese Pharmaceutical Journal 2017;52(20):1832-1836
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To investigate the synergetic effect of schisandrin B and liposomes on overcoming multidrug resistance(MDR). METHODS: Co-delivery of doxorubicin and schisandrin B by liposome(DS-L) were prepared, and doxorubicin solution(F-DOX), schisandrin B and doxorubicin mixture(Sch B+DOX), doxorubicin liposomes(D-L), doxorubicin liposomes and schisandrin B mixture(D-L+Sch B), verapamil and doxorubicin mixture(Ver+DOX) were also prepared as the control. The MTT test were measured, and the amount of doxorubicin in the K562/DOX cells at different time were determined, and time course of uptake and efflux were drawn. RESULTS: The MTT test shows that the resistance factor(RF) of group DS-L were 1.68, 14.52 and 1.42 times of group Sch B+DOX, group D-L and group D-L+Sch B respectively. The uptake test shows that amount of doxorubicin of K562/DOX cells in group DS-L was 1.30 and 1.21 times of that in group D-L and group Sch B+DOX respectively. And the efflux test shows DS-L could delay doxorubicin efflux from K562/DOX cells. CONCLUSION: The co-delivery of chemotherapeutics and P-gp inhibitors schisandrin B by liposome is a promising approach to overcome MDR. And there is a synergistic effect between liposome and schisandrin B to overcome MDR.
